Respiratory syncytial virus

Where the papers sit

13 papers from the last 6 months study respiratory syncytial virus directly · updated from PubMed 9 Oct 2026

• Respiratory Virus Research

  Fusion-protein binding and replication remain central targets for RSV antiviral discovery. Lianhua Qingwen, Pyrola compounds, and AhR ligands are being assessed through docking, surface plasmon resonance, network pharmacology, and protein-expression assays. Lipid nanoparticles are moving toward more efficient delivery through cholesterol analogs and vitamin-conjugated ionizable lipids. Metatranscriptomic surveillance adds a separate emphasis on detecting respiratory viruses and monitoring environmental burden.

  5 papers · 38.5%

• Respiratory Virus Countermeasures

  RSVpreF vaccination is being evaluated primarily through cost-effectiveness and reductions in respiratory illness, emergency visits, and healthcare use among older and high-risk adults. Parallel antiviral work is testing cyclophilin inhibitors and phloroglucinol compounds for broader respiratory-virus activity. mRNA sequence optimization points toward improving the design and production of future RNA-based countermeasures. The cluster therefore combines established vaccine health economics with early-stage antiviral and platform development rather than a single convergent strategy.

  5 papers · 38.5%

• Maternal RSV Vaccine Uptake

  Maternal RSV vaccination is moving from product introduction toward implementation shaped by confidence, communication, and shared responsibility. Pregnant women’s and caregivers’ perceptions remain closely tied to vaccine hesitancy and acceptance of infant monoclonal antibodies. The 5C framework highlights confidence, constraints, social influence, and collective responsibility as practical intervention points. National prioritization exercises are beginning to connect these behavioral findings with decisions about vaccine introduction and timing.

  3 papers · 23.1%